Skip to main content

Table 1 Demographics and Baseline Characteristics of Pediatric Patients Treated with Infliximab

From: Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis

Demographics and Clinical CharacteristicsNumber of patients (% of population)
Female, n = 2718 (67%)
Race, n = 27
 Caucasian22 (82%)
 African-American2 (7%)
 Hispanic2 (7%)
 Asian1 (4%)
Juvenile idiopathic arthritis, n = 1717 (63%)
 Extended Oligoarticular3 (3 ANA+)
 RF-negative, Polyarticular11 (9 ANA+)
 Enthesitis-related1 (HLA-B27 +)
 Juvenile psoriatic arthritis1 (ANA+)
 Undifferentiated1 (ANA+)
Idiopathic7 (26%)
Sarcoidosis1 (4%)
HLA-B27-associated1 (4%)
Other1 (4%)
Serology, n = 27
 ANA positive14 (52%)
 RF positive0
 HLA-B271 (4%)
 HLA-B51a1 (4%)
Uveitis Laterality, n = 27
 Bilateral23 (85%)
 Unilateral4 (15%)
Uveitis Location, n = 27
 Anterior19 (70%)
 Intermediate5 (19%)
 Anterior Intermediate2 (7%)
 Panuveitis1 (4%)
Age (Mos) of JIA Diagnosis (n = 17)
Ave ± SD (median)
43.6 ± 36.0 (23)
Age (Mos) of Uveitis Diagnosis (n = 27)
Ave ± SD (median)
86.5 ± 53.5 (76)
Duration of uveitis (Mos) prior to IFX start date, (n = 27) Ave ± SD (median)39.6 ± 36.0 (22)
Follow-up Duration (Mos) on IFX, (n = 27) Ave ± SD (median)41.6 ± 31.2 (35)
Previous Treatments prior to IFX Startb, n = 27
 Methotrexate (MTX)21 (78%)
 Adalimumab (ADA)c14 (52%)
 Etanercept (ETN)1 (4%)
 Oral prednisone within 2 years prior to IFX start7 (65%)
Indications for IFX
 Active uveitis in ≥1 eye pre-IFX [n = 27]19 (70%)
 Active uveitis OR < 0.5+ cell, but > 2 drops PA 1% to control disease [n = 27]24 (90%)
Active JIA (joint disease) [n = 17]11 (65%)
  1. aNot routinely tested
  2. bNo patients were treated with cyclosporine or mycophenolate
  3. cAdalimumab was dosed at 20 mg every other week for patients 15 kg to < 30 kg and 40 mg for patients ≥30 kg. Three patients failed weekly weight-based therapy of adalimumab
  4. Abbreviations: Mos months, Ave average, SD standard deviation, PA 1% Prednisolone acetate 1%, MTX methotrexate, ADA adalimumab, IFX infliximab, RF rheumatoid factor, ANA+ anti-nuclear antibody positivity